Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Extension Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients With Severe Hypertriglyceridemia (SHTG)

NCT05681351 is registered in ClinicalTrials.gov with Ionis Pharmaceuticals, Inc. as lead sponsor.

NCT NCT05681351
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05681351 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Extension Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Patients With Severe Hypertriglyceridemia (SHTG)
Lead sponsor
Ionis Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
December 13, 2022
Completion date
March 31, 2027
Enrollment
885 (actual)
Sites
262

Conditions

As the registry lists them; a condition with its own page is linked.

severe hypertriglyceridemia